News and Stories | Arnold Ventures

Research on Gun Violence Putting Data at the Center of the Gun Violence Policy Discussion

Alternatives to Arrest

‘She Literally Saved My Life’

Criminal Justice

What to Expect in 2020: Affordable Health Care, Criminal Justice Reform and More

Research on Gun Violence

Gun Violence in the United States Is a Crisis of Public Health and Public Safety — and Philanthropy Is Stepping Up

As Democrats Debate in Des Moines, Health Care Reform Tops Iowans' Wish Lists

A Small Win on Drug Pricing Was Added to the U.S. Budget, but Does it Go Far Enough?

Five States Join Urban Institute’s Prison Research and Innovation Network Research on Gun Violence Determining What’s Next for Assessing the State of Firearms Data

Our Top 10 Stories of 2019

The Opioid Epidemic

Study: Drug Maker's Anticompetitive Tactics Hindered Access to Lifesaving Opioid Medication

Podcast: ‘Dollar Signs in Uniform’: How For-Profit Education Continues to Target GI Bill Money Deep Dive with Laura Arnold

Laboratories of Democracy: States Ring in New Year with Ambitious New Health Laws

Thumbs Up, Thumbs Down: The Democratic Debate Edition

Research Aims to Illuminate the Impact of New York's Sweeping Bail Reform

Christmas for Data Geeks: After Yearslong Delay, Government Unveils Medicaid Data Set

Research on Gun Violence

You'll Shoot Your Eye Out: What ‘A Christmas Story’ Can Teach Us About Gun Laws

Research Into Student Success Programs

Is California Saving Higher Education?

Scrutiny of Colleges That Get Billions in GI Bill Money Remains Mired in Bureaucracy

Commercial Sector Prices

The Surprising Force Behind Surprise Medical Bills

A Landmark Drug Pricing Bill Just Cleared the House. Now What?

Podcast: The Fight for $15: Are Minimum Wage Increases a Path Out of Poverty or a Jobs Killer? Deep Dive with Laura Arnold

Alternatives to Arrest

How a Town at the Epicenter of the Opioid Crisis Became a Model for Recovery

Commercial Sector Prices

Hospital Price Transparency Is Necessary, but Not Sufficient

With New Chief in the Wings, Here’s How the FDA Could Wield Influence to Lower Drug Prices